Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.54 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.49 |
| ▸ | BCL2 | P10415 | 8/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.44 |
| ▸ | ACE | P12821 | 3/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | PREP | P48147 | 1/20 | 0.43 |
| ▸ | BAD | Q92934 | 2/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15675696 | 1.00 | OPRM1 (0.54) | OPRM1OPRL1KCNH2NOTUMBCL2 | |
| SCHEMBL20738536 | 1.00 | OPRM1 (0.54) | OPRM1OPRL1KCNH2NOTUMBCL2 | |
| SCHEMBL20738634 | 0.88 | OPRM1 (0.52) | OPRM1OPRL1KCNH2NOTUMBCL2 | |
| SCHEMBL20738516 | 0.86 | MTNR1B (0.49) | OPRM1OPRL1KCNH2NOTUMBCL2 | |
| SCHEMBL17559495 | 0.85 | BCL2 (0.47) | BCL2TDP1ACEBAD | |
| SCHEMBL4595358 | 0.85 | BCL2 (0.47) | BCL2TDP1ACEBAD | |
| SCHEMBL17559498 | 0.85 | BCL2 (0.47) | BCL2TDP1ACEBAD | |
| SCHEMBL24925815 | 0.84 | BCL2 (0.44) | OPRM1OPRL1KCNH2BCL2ACE | |
| SCHEMBL8274419 | 0.83 | BCL2 (0.43) | OPRM1OPRL1KCNH2BCL2OPRD1 | |
| SCHEMBL15704250 | 0.83 | OPRM1 (0.56) | OPRM1OPRL1KCNH2NOTUMBCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346795-B2 | Substituted sulfonamides useful as antiapoptotic Bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-24 | — | — | US | disclosed |
| EP-2714681-B1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-06-24 | — | — | EP | disclosed |
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-15 | — | — | US | disclosed |
| EP-1325910-B1 | ALIPHATIC NITROGENOUS FIVE-MEMBERED RING COMPOUNDS | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-09-17 | — | — | EP | disclosed |
| US-7160877-B2 | Aliphatic nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. (JP) | 2007-01-09 | — | — | US | disclosed |
| US-7160877-B2 | Aliphatic nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. (JP) | 2007-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BCL2, BAX, BCL2A1 | OPRM1 4690/4885OPRL1 3672/4885KCNH2 1587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.